

CardioGenics Retains Leading Investor Relations Firm

MISSISSAUGA, Ontario - October 06, 2010 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that it has retained The Equicom Group Inc. (Equicom) to provide investor relations services in North America.

"CardioGenics is working tirelessly to advance commercialization efforts of its products and is also moving rapidly to test its QL Care Platform as it anticipates a potential future FDA approval," said Dr. Yahia Gawad, CEO of CardioGenics. "Equicom, a leading IR firm in the healthcare and life sciences space, positions us to enhance our communications around these advancements, increase our profile and broaden our awareness amongst the financial community."

Equicom provides strategic communications services to approximately 120 public companies across a diverse range of industries.

About The Equicom Group Inc.

The Equicom Group, a wholly-owned subsidiary of TMX Group Inc., is a leading Canadian provider of investor relations and strategic corporate communications services. With proven expertise in developing and executing highly effective strategic communications programs, and an extensive network of investment community contacts, Equicom specializes in helping clients achieve their capital markets objectives. Equicom offers a comprehensive suite of services including: investor relations, media relations, annual report production, multimedia and web design, live event management and corporate branding. Equicom is headquartered in Toronto, with offices in Calgary and San Diego.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere™ magnetic beads are developed and marketed through the Company's Luxspheres subsidiary. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com and www.luxspheres.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and

the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.